New antibody trial aims to help immune system fight advanced cancers

NCT ID NCT04725474

Summary

This trial is testing a new drug called CTL-002 (visugromab) for adults with advanced solid tumors that have returned or stopped responding to standard treatments, including immunotherapy. The study has two parts: first finding a safe dose, then testing that dose in combination with an approved immunotherapy drug across seven specific cancer types. The main goals are to check the safety of the drug and see if it can help shrink tumors or stop them from growing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos

    Pamplona, 31008, Spain

  • Hospital Universitari Vall d'Hebron, Institute of Oncology

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • ICMDiM, Hospital Clinic

    Barcelona, 08036, Spain

  • ICO Hospitalet, Hospital Duran i Reynals

    Barcelona, 08908, Spain

  • Kantonsspital St. Gallen, Clinic for Medical Oncology & Hematology

    Sankt Gallen, 9007, Switzerland

  • Next Oncology, Phase I Unit. IOB - Hospital Quironsalud

    Barcelona, 08023, Spain

  • START Madrid, Hospital Universitario HM Sanchinarro

    Madrid, 28050, Spain

  • University Hospital Basel, Department for Medical Oncology

    Basel, 4031, Switzerland

  • University Hospital Zurich, Department of Dermatology

    Zurich, 9091, Switzerland

  • Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik

    Essen, 45147, Germany

  • Universitätsklinikum Frankfurt, Medizinische Klinik I

    Frankfurt am Main, 60590, Germany

  • Universitätsklinikum Würzburg, Comprehensive Cancer Center

    Würzburg, 97078, Germany

Conditions

Explore the condition pages connected to this study.